自体DC-CIK细胞治疗晚期实体瘤患者的疗效分析  

Clinical efficacy of autologous DC-CIK cells therapy for patients with advanced solid tumors

作　　者：冉宝石 王伟[1] 王刚[1] 孙玉蓓[1] 王保龙[1] 季楚舒[1] 

机构地区：[1]安徽医科大学附属省立医院肿瘤化疗科,合肥230001

出　　处：《安徽医科大学学报》2016年第7期1053-1058,共6页Acta Universitatis Medicinalis Anhui

基　　金：国家自然科学基金(编号:81172172)

摘　　要：目的研究树突状细胞联合细胞因子诱导的杀伤细胞(DC-CIK)治疗对晚期肿瘤患者免疫系统影响及临床疗效。方法选取60例患者,分为两组,试验组行两周期DCCIK治疗,对照组未治疗,对比试验前后外周血免疫细胞比例及生活质量变化,观察疗效及不良反应。结果试验组总缓解率为0,疾病控制率约36.67%,外周血CD4+T细胞、自然杀伤细胞(NK)及CIK细胞比例较前升高(P<0.05),CD8+T细胞比例下降(P<0.05),患者生活质量较前改善,不良反应为低热、过敏等;对照组CD4+T细胞、NK细胞及CIK细胞比例较前下降(P<0.05),而CD8+T细胞比例升高(P<0.05),患者生活质量较前下降。两组B细胞比例均无明显变化。结论 DC-CIK可改善晚期实体瘤患者免疫功能和一般状况,在临床治疗中有一定疗效,且副作用小,可作为放化疗失败后的选择之一。Objective To study the influence of immune system and clinical efficacy of DC-CIK cells therapy for patients with advanced solid tumors. Methods Sixty patients were divided into two groups. The treatment group was received two cycles＇ reinfusion of DC-CIK cells,while the control group was not. The changes of proportional of immune cells and quality of life were compared before and after the treatment,and the clinical efficacy and adverse reactions were also detected. Results In the treatment group,the overall response rate was 0.00%,and the disease control rate was 36.67%. The ratios of CD4^＋T lymphocytes,NK and CIK cells were higher than before,but the ratio of CD8^＋T lymphocytes was less. Patients＇ overall quality of life was improved and the adverse reactions were fever,allergies etc. In the control group,the ratios of CD4^＋T lymphocytes,NK and CIK cells are less than before,but the ratio of CD8^＋T lymphocytes was higher. Patients＇ overall quality of life was decline. and the ratio of B lymphocytes in both groups didn＇t change significantly. Conclusion DC-CIK cells therapy can improvethe patients＇ with advanced solid tumors immune function and general situations,which has a certain clinical effect and its adverse reactions are less,so it can be used as one option for the patients who suffer the failures of chemotherapy and radiotherapy.

关 键 词：树突状细胞 细胞因子诱导的杀伤细胞 晚期实体瘤 淋巴细胞亚群 生活质量 

分 类 号：R730.51[医药卫生—肿瘤]